Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   Koersverloop Pharming in juli

Aandeel Pharming Group NL0010391025

Laatste koers (eur) Verschil Volume
0,708   -0,009   (-1,19%) Dagrange 0,700 - 0,732 8.571.432   Gem. (3M) 5,6M

Koersverloop Pharming in juli

Volgen
684 Posts
Pagina: «« 1 ... 8 9 10 11 12 ... 35 »» | Laatste | Omlaag ↓
  12. [verwijderd] 10 juli 2015 22:06
    quote:

    voda schreef op 10 juli 2015 21:28:

    [...]
    Ja, nu hoor je geen "kwaad" woord. Hoe opvallend. LOL :-)

    PS: Volgende week zakt het weer, wordt er fors "bijgekocht" natuurlijk.
    Het blijft feest bij de RBG. (en onbeperkt diepe zakken natuurlijk)
    Ja Hans ik zie het, twee centen erbij. Mooi. Ehm. Top aandeel. Die handelaren ook. Intrinsiek is het natuurlijk centen meer waard. Ik schenk maar wat in en bezie het met een glimlach. Goed weekend!
  15. CW1884 12 juli 2015 18:42
    In de newsletter van juni staat onder andere het volgende:

    Recent activities

    This is a brief overview of some of HAEi’s activities in the recent
    months:

    7-10 June HAEi was in Barcelona, Spain participating in this
    years EAACI conference. The event was a great opportunity to
    catch up both with healthcare professionals and industry.

    25-26 June HAEi took part in a Pharming Advisory Board
    meeting in Berlin, Germany.

    2-3 July HAEi met with Clinigen Group in London, United
    Kingdom to get an overview of the Global Access Program and
    status for final launch.
  16. CW1884 12 juli 2015 18:44
    Future activities

    16-17 September HAEi will participate in and host a round-table
    discussion on patients’ access to medication at the Orphan Drug
    Summit 2016 in Copenhagen, Denmark.

    2-4 October HAEi will participate in the annual patient meeting
    of our Polish member organization. This year the meeting will
    take place in Warsaw, Poland.

    9-11 October HAEi will participate in the US HAEA National
    Patient Summit 2015 in Denver, Colorado, USA. This summit is
    expected to attract 6-700 delegates.

    20-21 October HAEi is planning on participating in the WHINN
    (Weak of Health and Innovation) which will take place in
    Odense, Denmark. The goal is to gather more information
    about possibilities in healthcare technology and how HAEi can
    better utilize technology on a global basis.

    28-29 October HAEi is planning on participating in the
    EURORDIS Council of European Federations meeting in Paris,
    France.

    The HAEi Executive Committee will meet in Frankfurt,
    Germany 30 October-1 November.

    6 – 8 November HAEi will participate in and speak at the first
    HAE Scandinavian conference taking place in Nyborg,
    Denmark.
  17. CW1884 12 juli 2015 18:48
    Romania (www.haenet.ro):

    Dr. Dumitru Moldovan from the Romanian
    Network for HAE writes about the recent
    achievements in the emergency management of
    HAE attacks in Romania:

    “In the past eight years a pilot centre was built up and patients
    confirmed with C1-INH were included in a national register of
    HAE. An HAE patients association was founded two years ago. In
    the past two years a sustained effort was made to put together
    experts on HAE, patients’ representatives, emergency department
    leaders and authorities in Romania to start the first program of
    emergency care of HAE attacks. Interviews with states secretaries
    responsible for the emergency medical care from Ministry of
    Health and Ministry of Internal Affairs were planned.

    As of March 2015, the Registry of HAE patients includes 91
    patients from 31 families. In the past year, these patients have
    recorded 920 peripheral, 770 abdominal, 170 facial, and 80
    upper respiratory attacks.

    Since summer 2013 a gradual positive attitude of the Ministry of
    Health was noted regarding the reimbursements of new drugs
    approved for treatment of HAE attacks. Data from the Romanian
    Registry of HAE patients were provided and direct costs of
    treatment of facial, upper respiratory and abdominal attacks were
    evaluated. Elaboration of a protocol for treatment of HAE
    attacks is ongoing. A 24/7 telephone HAE expert consultancy is
    offered.

    Ruconest meets legal requirements for reimbursement -
    acquisition has been started and the first vials were administered.

    (Ruconest voldoet aan de wettelijke eisen voor vergoeding -
    acquisitie is gestart en de eerste flesjes werden toegediend.    )

    The recent developments on the cooperation between patients’
    organization, HAE experts, emergency departments and
    authorities enable us to hope a new era is coming to HAE patients
    in Romania.”
  18. CW1884 12 juli 2015 19:00
    Kenya (https://www.facebook.com/
    100009028142543):

    Patricia Karani, the National Patient
    Representative in Kenya, writes that the
    postings about Kenya in this newsletter has
    made the first person contact her inquiring about HAE in the
    country. Ms. Karani writes:

    “Kenya is really an uphill task from physicians who are not as
    knowledgeable about the disease to the fact that there are no
    ISSUE 4 JULY 2015
    HAEI NEWSLETTER 13 www.haei.org
    prophylaxis or anaphylaxis medicines in this country. I have
    searched for some form of medication for the past six months and
    I discovered Danazol 200mg in only one pharmacist in Nairobi.
    Danazol is rare and it has run out of stock in the country. In
    Kenya we have to beg doctors to listen and show interest. It is
    really very difficult. It is my prayer that a teleconference with the
    participation of a doctor from Aga Khan Hospital in Nairobi,
    representatives of HAEi and US HAEA and myself will be the
    first great step to help our medical fraternity take up some form
    of interest for this condition and the beginning towards finding
    other patients in Nairobi and Kenya.”
  19. CW1884 12 juli 2015 19:02
    Venezuela (Angioedema-Hereditario-DeVenezuela/1475867039316898):

    Ruconest is on its way to the patients in the
    South American country: In May Pharming
    Group NV entered into an exclusive
    distribution agreement with Cytobioteck S.A.S., a privately
    owned Bogota, Colombia based specialty healthcare company, for
    the distribution of Ruconest for the treatment of acute attacks of
    HAE in Colombia and Venezuela. Soon after the drug was tested
    on an intensive care patient with very positive results - and most
    recently CEO Osvaldo Piñeros from Cytobioteck, Regulatory
    Affairs Manager Carlos Zorrilla from Netmedical and Ms. Mary
    Bocaranda from HAE Venezuela met in order to discuss a work
    plan for the acquisition of drugs nationwide in Venezuela through
    the Social Security Institute.
  20. Grunniger 12 juli 2015 21:34
    Je hebt je best gedaan CW1884 zie ik.

    Het zou mooi zijn als we eens wat berichten krijgen vanuit phamring over de eerste verkopen i.p.v. via via.

    Ik hoop dat er een stijging zit in de verkoop en dat die zo groot is dat men weer wat vertrouwen krijgt. Ik heb sterk mijn twijfels over de cijfers van Q2.
    hoe staat het eigenlijk met de kennis die vorig jaar in frankrijk is overgenomen van Franse branchegenoot TRM SASU:
    vijf nieuwe productontwikkelingen, onder meer voor de behandeling van de ziekte van Pompe, de ziekte van Farby en de ziekte van Gauche
684 Posts
Pagina: «« 1 ... 8 9 10 11 12 ... 35 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Sterk eindschot voor Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. Video: omvangrijke investeringen in defensie risico voor rentegevoelige aandelen
  2. Pharming meldt start trial voor nieuwe indicatie leniolisib
  3. Beursherstel lijkt niet houdbaar en hoe worden cijfers Pharming ontvangen?
  4. Beursblik: meevallende omzet Pharming
  5. Operationele winst Pharming stijgt
  6. Groen licht voor nieuwe CEO Pharming
  7. Rode koersenborden nu de mondiale handelsoorlog echt is begonnen
  8. Groene futures, Trump praat crypto's de lucht in en spanningen China nemen toe
  9. Pharming heeft bijna 93% van Abliva in handen
  10. Pharming verklaart bod op Abliva onvoorwaardelijk